Synlogic (SYBX) Stock Price, News & Analysis

Company Overview

Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts.

Key Stats

• Today's Range: $1.37 to $1.42
• 50-Day Range: $1.36 to $1.53
• 52-Week Range: $1.22 to $5.12
• Volume: 31,389 shs
• Average Volume: 64,081 shs
• Market Capitalization: $16.61 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Hold

SYBX Stock Analysis - Frequently Asked Questions

How have SYBX shares performed this year?

Synlogic's stock was trading at $3.85 at the beginning of 2024. Since then, SYBX stock has decreased by 63.1% and is now trading at $1.42.
View the best growth stocks for 2024 here.

How were Synlogic's earnings last quarter?

Synlogic, Inc. (NASDAQ:SYBX) issued its quarterly earnings data on Tuesday, November, 12th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.17. Synlogic had a negative trailing twelve-month return on equity of 207.84% and a negative net margin of 2,284.65%.

When did Synlogic's stock split?

Shares of Synlogic reverse split before market open on Thursday, September 28th 2023. The 1-15 reverse split was announced on Thursday, September 28th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, September 28th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Who are Synlogic's major shareholders?

Top institutional investors of Synlogic include FMR LLC (1.42%). Insiders that own company stock include Antoine Awad, Aoife Brennan, Mary Beth Dooley and Michael Vangsted Jensen.
View institutional ownership trends.

How do I buy shares of Synlogic?

Shares of SYBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Synlogic own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Synlogic investors own include Reata Pharmaceuticals (RETA), Sangamo Therapeutics (SGMO), Approach Resources (AREX), Precision Drilling (PDS), First Financial Bankshares (FFIN), Sorrento Therapeutics (SRNE) and Exelixis (EXEL).

Company Calendar

• Last Earnings: 11/12/2024
• Today: 12/21/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SYBX
• CUSIP: N/A
• CIK: 1527599
• Web: www.synlogictx.com
• Phone: (617) 401-9975
• Fax: 512-681-5201
• Employees: 6
• Year Founded: 2013

Profitability

• EPS (Most Recent Fiscal Year): ($4.16)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-57,280,000.00
• Net Margins: -2,284.65%
• Pretax Margin: -1,591.50%
• Return on Equity: -207.84%
• Return on Assets: -114.81%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.71
• Quick Ratio: 2.71

Sales & Book Value

• Annual Sales: $3.37 million
• Price / Sales: 4.93
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.64 per share
• Price / Book: 0.31

Miscellaneous

• Outstanding Shares: 11,700,000
• Free Float: 11,343,000
• Market Cap: $16.61 million
• Optionable: Optionable
• Beta: 0.83